2. Academic Validation
  3. Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy

  • NPJ Precis Oncol. 2023 Jul 21;7(1):70. doi: 10.1038/s41698-023-00417-5.
Zechen Wang 1,  Viswanathan Muthusamy 2,  Daniel P Petrylak 3,  Karen S Anderson 4 5
Affiliations

Affiliations

  • 1 Department of Pharmacology, Yale University School of Medicine, 333 Cedar St., New Haven, CT, 06520, USA.
  • 2 Center for Precision Cancer Modeling, Yale School of Medicine, New Haven, CT, USA.
  • 3 Smilow Cancer Center, Yale University, New Haven, CT, USA.
  • 4 Department of Pharmacology, Yale University School of Medicine, 333 Cedar St., New Haven, CT, 06520, USA. karen.anderson@yale.edu.
  • 5 Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 333 Cedar St., New Haven, CT, 06520, USA. karen.anderson@yale.edu.
PMID: 37479885 DOI: 10.1038/s41698-023-00417-5
Abstract

Bladder Cancer (BC) is one of the most prevalent malignancies worldwide and FGFR3 alterations are particularly common in BC. Despite approval of erdafitinib, durable responses for FGFR inhibitors are still uncommon and most patients relapse to metastatic disease. Given the necessity to discover more efficient therapies for BC, herein, we sought to explore promising synergistic combinations for BC with FGFR3 fusions. Our studies confirmed the synergy between FGFR and HDAC inhibitors in vitro and demonstrated its benefits in vivo. Mechanistic studies revealed that quisinostat can downregulate FGFR3 expression by suppressing FGFR3 translation. Additionally, quisinostat can also sensitize BC cells to erdafitinib by downregulating HDGF. Furthermore, the synergy was also confirmed in BC cells with FGFR3 S249C. This study discovers a new avenue for treatment of FGFR3-driven BC and uncovers new mechanistic insights. These preclinical studies pave the way for a direct translation of this combination to early phase clinical trials.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z